Overview / Abstract: |
Target Audience Program Overview Learning Objectives Evaluate recent clinical evidence for anti-EGFR and anti-TROP2 targeted therapies to treat patients with NSCLC |
Expiration |
Mar 30, 2025 |
Discipline(s) |
Physician CME |
Format |
Online |
Credits / Hours |
1.0 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty Shahryar Ashouri, MD |
Sponsors / Supporters / Grant Providers |
AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. |
Keywords / Search Terms |
Relias LLC Relias LLC., FreeCME., Lung Cancer, Anti-EGFR and Anti-TROP2 Therapies Free CE CME |